Breast Cancer Clinical Trial
Official title:
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Peripheral stem cell transplantation may be able to replace
immune cells that were destroyed by chemotherapy. Donor lymphocytes may attack and destroy
cancer cells.
PURPOSE: This phase II trial is studying the effectiveness of combination chemotherapy,
peripheral stem cell transplantation, and donor lymphocyte infusion in treating women with
stage IV breast cancer.
OBJECTIVES: I. Determine the tumor response in women with stage IV breast cancer who achieve
partial remission after a mini-conditioning regimen comprising fludarabine and
cyclophosphamide, followed by allogeneic peripheral blood stem cell transplantation (PBSCT),
and donor lymphocyte infusion (DLI). II. Determine the progression free survival in patients
who achieve complete remission after this treatment regimen. III. Determine whether DLI
exerts graft versus tumor effect in these patients. IV. Determine the acute and delayed
toxicities of this regimen in these patients. V. Determine the rates of durable hematologic
engraftment in patients treated with this regimen. VI. Determine the incidence and severity
of acute and chronic graft versus host disease in patients treated with this regimen. VII.
Determine the extent of chimerism in patients treated with this nonmyeloablative
conditioning regimen. VIII. Determine the rate and quality of immune reconstitution in
patients treated with this regimen. IX. Determine the event free and overall survival in
patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients receive salvage chemotherapy comprised of
docetaxel IV over 1 hour and doxorubicin IV over several minutes on day 1. Treatment
continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable
toxicity. Beginning within 4-10 weeks after completion of salvage chemotherapy, patients
achieving complete or partial remission or stable disease receive mini-conditioning
comprised of fludarabine IV over 30 minutes on days -8 to -4 and cyclophosphamide IV over 2
hours on days -3 and -2. Patients then receive filgrastim (G-CSF) and sargramostim (GM-CSF)
mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0. Beginning on day 120
after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion
(DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence
of grade III or IV graft versus host disease or marrow aplasia. Patients are followed every
3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 30-50 patients will be accrued for this study.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |